FDA Grants Seastar Medical's Selective Cytopheretic Device Breakthrough Device Designation For Hepatorenal Syndrome

  • Kevin Chung

Press/Media

Period18 Oct 2023

Media coverage

1

Media coverage

  • TitleFDA Grants Seastar Medical's Selective Cytopheretic Device Breakthrough Device Designation For Hepatorenal Syndrome
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    Country/TerritoryJordan
    Date18/10/23
    PersonsKevin Chung